Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer

Journal of Pharmaceutical Sciences

Volumn 94, Issue 9, 2005, Pages 1957-1964

  Lobo, Evelyn D ^a,b   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; Cancer; Chemotherapy; Drug targeting

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; METHOTREXATE; METHOTREXATE DERIVATIVE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PERITONEUM CANCER; PERITONEUM TUMOR; SURVIVAL TIME;

EID: 27644441819     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20422     Document Type: Article

References (21)

1. Balthasar J, Fung HL. 1994. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: Studies using digoxin as a model drug. J Pharmacol Exp Ther 268:734-739.
2. Balthasar JP, Fung HL. 1996. Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of antimethotrexate antibodies and antibody fragments. J Pharm Sci 85:1035-1043.
3. Lobo ED, Soda DM, Balthasar JP. 2003. Application of pharmacokinetic- pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharm Sci 92:1665-1676.
4. Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS. 2000. Protection against lipopolysaccharide-induced death by fluoroquinolones. Antimicrob Agents Chemother 44:3169-3173.
5. Tayab ZR, Balthasar JP. 2004. Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. J Immunoassay Immunochem 25:333-342.
6. Lobo ED, Balthasar JP. 2003. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci 92:1654-1664.
7. Cintron JR, Pearl RK. 1996. Colorectal cancer and peritoneal carcinomatosis. Semin Surg Oncol 12: 267-278.
8. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis J, Jr., Barakat R, Rubin S, Mychalczak B, Saigo P, et al. 1993. Intraperitoneal chemotherapy in the management of ovarian cancer. [Review]. Cancer 71:1565-1570.
9. Patel SR, Benjamin RS. 2000. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 9:67-70.
10. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. 1978. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports 62:1-11.
11. Alberts DS, Liu PY, Hannigan EV, R OT, Williams SD, Young JA, Franklin EW, Clarke Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ. 1996. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955.
12. Hasuda K, Kobayashi H, Kuroiwa T, Aoki K, Taniguchi S, Baba T. 1989. Efficacy of two-route chemotherapy using intraperitoneal neocarzinostatin and its antidote, intravenous tiopronin, for peritoneally disseminated tumors in mice. Jpn J Cancer Res 80:283-289.
13. Howell SB, Taetle R. 1980. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treatment Reports 64:611-616.
14. Wagner T, Mittendorff F, Walter E. 1986. Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor. Cancer Res 46:2214-2219.
15. Howell SB. 1988. Intraperitoneal chemotherapy for ovarian carcinoma. [Review]. J Clin Oncol 6:1673-1675.
16. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M. 1982. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851.
17. Balsari A, Menard S, Colnaghi MI, Ghione M. 1991. Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. Int J Cancer 47:889-892.
18. Gutowski MC, Fix DV, Corvalan JR, Johnson DA. 1995. Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody. Cancer Invest 13: 370-374.
19. Sardini A, Villa E, Morelli D, Ghione M, Menard S, Colnaghi MI, Balsari A. 1992. An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. Int J Cancer 50: 617-620.
20. Balthasar JP, Fung HL. 1995. High-affinity rabbit antibodies directed against methotrexate: Production, purification, characterization, and pharmacokinetics in the rat. J Pharm Sci 84:2-6.
21. Graczyk J. 1981. Acute toxicity of methotrexate and cyclophosphamide in mice inoculated with malignant neoplasms. Pol J Pharmacol Pharm 33:73-80.